KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to $12.0 billion.

  • BioNTech SE's Cash & Equivalents fell 627.43% to $12.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 billion, marking a year-over-year decrease of 627.43%. This contributed to the annual value of $10.4 billion for FY2024, which is 3012.47% down from last year.
  • Per BioNTech SE's latest filing, its Cash & Equivalents stood at $12.0 billion for Q3 2025, which was down 627.43% from $11.5 billion recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Cash & Equivalents ranged from a high of $1459786.9 billion in Q1 2021 and a low of $1.4 billion during Q3 2021
  • For the 5-year period, BioNTech SE's Cash & Equivalents averaged around $76840.3 billion, with its median value being $12.0 billion (2025).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 9999.99% in 2022, then surged by 68391.8% in 2023.
  • Over the past 5 years, BioNTech SE's Cash & Equivalents (Quarter) stood at $1.9 billion in 2021, then surged by 631.05% to $14.2 billion in 2022, then grew by 5.46% to $14.9 billion in 2023, then tumbled by 30.12% to $10.4 billion in 2024, then rose by 15.09% to $12.0 billion in 2025.
  • Its Cash & Equivalents was $12.0 billion in Q3 2025, compared to $11.5 billion in Q2 2025 and $10.3 billion in Q1 2025.